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Objective: To assess the pain and functional disability levels corresponding to an indication for total joint
replacement (TJR) in hip and knee osteoarthritis (OA).
Methods: Design: International cross-sectional study in 10 countries. Patients: Consecutive outpatients
with deﬁnite hip or knee OA attending an orthopaedic outpatient clinic. Gold standard measure for
recommendation for TJR: Surgeon’s decision that TJR is justiﬁed. Outcome measures: Pain (ICOAP: inter-
mittent and constant osteoarthritis pain, 0e100) and functional impairment (HOOS-PS/KOOS-PS: Hip/
Knee injury and Osteoarthritis Outcome Score Physical function Short-form, 0e100). Analyses:
Comparison of patients with vs without surgeons’ indication for TJR. Receiver Operating Characteristic
(ROC) curve analyses and logistic regression were applied to determine cut points of pain and disability
deﬁning recommendation for TJR.
Results: In all, 1909 patients were included (1130 knee/779 hip OA). Mean age was 66.4 [standard
deviation (SD) 10.9] years, 58.1% were women; 628/1130 (55.6%) knee OA and 574/779 (73.7%) hip OA
patients were recommended for TJR. Although patients recommended for TJR (yes vs no) had worse
symptom levels [pain, 55.5 (95% conﬁdence interval 54.2, 56.8) vs. 44.9 (43.2, 46.6), and functional
impairment, 59.8 (58.7, 60.9) vs. 50.9 (49.3, 52.4), respectively, both P< 0.0001], there was substantial
overlap in symptom levels between groups, even when adjusting for radiographic joint status. Thus, it
was not possible to determine cut points for pain and function deﬁning ‘requirement for TJR’.
Conclusion: Although symptom levels were higher in patients recommended for TJR, pain and functional
disability alone did not discriminate between those who were and were not considered to need TJR by
the orthopaedic surgeon.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is amajor causeofdisabilityworldwide1.Over
the past years, interest has grown among the scientiﬁc community,
pharmaceutical companies, and regulatory agencies in the devel-
opment of drugs that might inﬂuence the natural history of struc-
tural changes in OA by preventing, retarding, or reversing cartilage
breakdown. Interest exists, therefore, in identifying a valid, dichot-
omous outcome variable that reﬂects the natural history of struc-
tural changes in OA. In particular, interest has grown in using the
requirement of total joint replacement (TJR) as a “hard” endpoint2,3.
Limitations exist, however, in the use of such an outcome. Perfor-
mance of TJR is a measure of utilization and not of a health state.
Numerous non-health related factors have been shown to inﬂuence
utilization including patient race, ethnicity, income, activity level
and preferences among others, and other non-musculoskeletal
health factors inﬂuence the decision to undergo TJR including
comorbidity2e10. Thus, a better alternativemight be to change “time
to TJR” to “time to fulﬁll the criteria for TJR”11. In this context and as
described elsewhere12,13, an international working group was
created under the auspices of Osteoarthritis Research Society
International (OARSI) and Outcome Measures in Rheumatology
Clinical Trials (OMERACT). The group’s charge was to elaborate a set
of criteria deﬁning a state corresponding to recommendation for TJR
in patients with symptomatic knee and hip OA, for use in clinical
trials evaluating potential disease-modifying drugs and other
interventions inOA. Itwasdecided that thedomainsof pain, physical
function and joint structureon radiographs14e16wouldbe combined
as a surrogate measure of outcome. The consensus was to consider
the level of symptoms (i.e., pain and function) at one point, and
a deﬁnition of radiological progression between two time-points16.
The ﬁnal binary outcome could then be used as a deﬁnition for
“responders/non-responders” in OA clinical trials. For each of these
domains, a categorical outcome needs to be used to render combi-
nation of the domains feasible. To this end, it is necessary to cate-
gorize or dichotomize the continuous variables pain and functional
disability.
Thus, the objective of the present study was to deﬁne cut points
for both pain and functional disability, leading to a jointreplacement indication. To this end, a data-driven approach, based
on real patient data, was chosen.
This article presents the results of a large cross-sectional study
performed to deﬁne cut-point levels for pain and functional disability
among patients with hip or knee OA being evaluated by orthopaedic
surgeons for possible need of TJR. The goalwas to use these cut-offs to
develop a theoretical indication for TJR, in hip and knee OA.
Patients and methods
Study design
This international prospective observational cross-sectional
study was conducted in the orthopaedics departments of tertiary-
care and secondary-care centers in Europe (12 centers, one per
country in the Czech Republic, Italy, Spain, Sweden, and the United
Kingdom; two per country in France and The Netherlands; three in
Germany), Canada (two centers), the United States of America (two
centers), and Australia (two centers).
Ethical approval was obtained from all participating centers.
Study population
Consecutive outpatients consulting with an orthopaedic surgeon
in one of the participating centers andwith a diagnosis of hip or knee
OA (according to the orthopaedic surgeon and based on symptoms
and radiographs) were included. Only patients for whom the
surgeon answered ‘There are deﬁnite radiographic signs of OA of the
target joint’ were included. Exclusion criteria were: no deﬁnite
diagnosis of OA, prior TJR or prior osteotomy of the target joint,
concomitant inﬂammatory arthritis (e.g., rheumatoid arthritis,
spondyloarthropathy), patient inability to ﬁll in a questionnaire or
patient refusal.
Gold standard: indication for TJR
The gold standard was deﬁned by the orthopaedic surgeon’s
opinion regarding the recommendation for TJR, operationalized as
the surgeon stating that (1) TJR was recommended for the patient
Table I
Patients’ characteristics
All patients
N¼ 1909
Knee patients
N¼ 1130
Hip patients
N¼ 779
Age, years 66.4 10.9 67.5 10.4 64.9 11.4
Sex, N (%) women 1086 (58.1) 657 (58.9) 429 (56.9)
OA symptom duration, years 5.4 6.9 6.3 7.7 4.1 5.5
Body mass index, kg/m2 29.9 6.3 31.0 6.8 28.3 5.2
Pain, ICOAP score 51.6 22.3 50.3 22.0 53.3 22.6
Functional disability,
HOOS-PS/KOOS-PS scores
56.5 20.0 55.5 18.8 57.8 21.5
Pain, WOMAC subscale 54.0 21.0 52.5 20.8 56.3 21.1
Function, WOMAC subscale 57.0 20.5 55.2 20.2 59.5 20.8
Radiographic joint space
narrowing, N (%)*
<25% 95 (10.7) 67 (13.0) 28 (7.8)
25e50% 131 (14.7) 95 (18.5) 36 (9.6)
50e75% 274 (30.8) 159 (31.0) 115 (30.6)
>75% 389 (43.8) 192 (37.4) 197 (52.4)
Results are presented as mean SD unless otherwise mentioned. Pain and func-
tional disability were linearly transformed to 0e100 scores where 100¼worst state.
* X-ray scoring was only available for 889 patients and % are % of available data.
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enough to indicate TJR but surgery was not indicated because of
comorbidity or patient declining surgery. These answers deﬁned an
‘indication for TJR’, irrespective of whether the joint replacement
surgery was performed or not.
Pain and functional disability
Two self-reported measures, pain and functional disability, were
collected using the intermittent and constant osteoarthritis pain
(ICOAP) score17,18 for pain, and the Hip disability and Osteoarthritis
Outcome Score (HOOS) for hip, and Knee injury and Osteoarthritis
Outcome Score (KOOS) for knee for function19e21. All scores had
Likert answer modalities. The scores were linearly transformed to
0e100 scores, where higher scores indicate worse status. These
questionnaires previously underwent translation and cross-cultural
adaptation into each of the participating countries’ languages18.
Clinical severity was also estimated through the pain, stiffness,
and function subscales of the Western Ontario and McMaster
Universities Osteoarthritis Index (WOMAC)22 with Likert answer
modalities. Results were also linearly transformed to a 0e100 score
where higher scores indicate worse status.
Symptom duration
The duration of symptoms, at their current level, was collected
by self-report.
Radiographic severity
The local investigator evaluated the radiographs of the target
joint, recording joint space narrowing as categories (none, <25%,
25e50%, 50e75%, >75%). Not all canters participated in the radio-
graphic evaluation of severity.
Other clinical data collection
Demographic data included age, and sex. Other information
included weight and height (body mass index was then calculated),
and date of onset of development of OA symptoms in the target joint.
Statistical analysis
1. Sample size: It was anticipated that 1000 knee OA and 1000
hip OA patients would be included, allowing the assessment of
Receiver Operating Characteristic (ROC) curves and areas under the
curve (AUCs) with a precision of 0.03 for an expected AUC of 0.8023.
Other sample size calculations based on expected sensitivities or
speciﬁcities, led to smaller sample sizes (data not shown).
2. Descriptive analysis of pain and functional disability: The
distributions of the two variables were analysed for both hip and
knee OA, according to the gold standard outcome (recommendation
for TJR yes/no) and compared using Student’s t test or the Wilcoxon
rank test. Pain and functionwere also categorized in deciles, and the
frequency of the positive gold standard was assessed (with exact
conﬁdence intervals, by the ClopperePearson method24) to describe
the relation between pain, function and indication for TJR.
3. Univariate ROC curves: This was the main planned analysis to
assess cut points for pain and functional disability. The ability of pain
and functional disability to predict the gold standard was assessed in
a univariate manner by a non-parametric ROC curve25 and its AUC
was calculated. The null hypothesis was that pain and functional
disability levels could not distinguish the groups ’recommended for
TJR yes/no’. The criteria for accepting the null hypothesis were AUCs
<0.65. If the null hypothesis was rejected, it was planned to assesscut points to maximise speciﬁcity (for a speciﬁcity of 90%, 95%, 98%)
but also sensitivity, and for each cut point, the sensitivity, the spec-
iﬁcity, and the likelihood ratios were assessed.
To take into account radiographic severity, the analyses were
stratiﬁed on radiographic severity by analysing the relationship
between symptoms and recommendation for TJR, for a radiographic
joint space narrowing<50%, 50e75%, andmore than 75% separately.
4. Correlation between pain and function was examined graphi-
cally and tested by Spearman’s correlation coefﬁcient.
5. Logistic regression: Pain and function were combined based on
logistic regression. In the logistic regression, pain and function were
entered into a bivariate model to predict theoretical indication for
TJR, with a stepwise selection mode. The goodness-of-ﬁt was
checked with HosmereLemeshow’s test26. The regression parame-
ters of the variables pain and function allowed the assessment of the
relative importance (weight) of these variables vs the gold standard,
thus allowing us to combine the two domains (b1painþ b2function
where b1 and b2 are the regression parameters of the variables pain
and function respectively). The combination was then tested using
non-parametric ROC curves as described above, and stratiﬁed on
radiographic severity as explained above.
6.Additional sensitivityanalyses: Analyseswere run separately for
the hip and knee. Potential heterogeneity across centers (regrouped
by country) was assessed. A modiﬁed version of the gold standard
question was modelled (‘surgeon saying the patient is referred for
TJR’, not taking into account patients not referred to surgery due to
comorbidities or patient refusal). Another statistical technique
involving the 75th percentile of the distribution of patients recom-
mended for TJR was applied. The 75th percentile gave the value of
the sum (painþ function) deﬁning 75% of the populationwhich had
an indication for TJR. Furthermore, the same analyses were per-
formed using WOMAC pain and function subscales. Finally, a sensi-
tivity analysis was performed, excluding patients from the United
Kingdom since for these patients, the questionnaires had been
administered differently.
All analyses were performed using the Statistical Analysis
System (SAS), version 9.1. Statistical signiﬁcance was set at 0.05.
Results
Patient characteristics (Table I)
In all, 1974 patients were included; 1909 had an answer for the
gold standard question and were analysed: 1130 knee OA and 779
hip OA patients (Table I). The patients were included in Europe
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(N¼ 261), and Canada (N¼ 204). Supplementary ﬁle 1 shows the
characteristics of the patients from the different centers.
Mean age of the patients was 66.4 [standard deviation (SD):
10.9] years, 58.1% were women, mean OA duration was reported as
5.4 (SD 6.9) years. Of the 1909 patients, 628 (55.6%) knee patients
and 574 (73.7%) hip patients were recommended for TJR. The
recommendationwas mainly related to the surgeon stating TJR was
indicated (91.7% of indications) and much less often to the answers
‘although the symptoms are severe enough, the patient declined
surgery’ (4.0%) or ‘there were comorbidities’ (4.3%). The frequency
of indication for TJR varied across countries, from 33.8% with an
indication for surgery among the patients from the Italian center, to
87.9% among the patients from the Czech Republic center.
Pain assessed by ICOAP and functional disability by
HOOS-PS/KOOS-PS (Table II)
Scores for pain and functional disability were not normally
distributed (Fig. 1 for online version only), but showed awide spread
in severity of symptoms. Pain had the following distribution in knee
OA: mean SD 50.3 22.0, median 50.0 (ﬁrst quartile¼ 31.8, third
quartile¼ 68.2, range 0e100) and in hip OA: mean SD 53.3 22.6,
median 54.5 (ﬁrst quartile¼ 4.1, third quartile¼ 70.5, range 0e100).
Functional impairment had the following distribution in knee OA:
mean SD 55.518.8, median 51.2 (ﬁrst quartile¼ 42.0, third
quartile¼ 66.6, range 0e100) and in hip OA: mean SD 57.8 21.5,
median 55.9 (ﬁrst quartile¼ 41.7, third quartile¼ 74.8, range 0e100).
Pain and functional disability levels and their duration, for those
who did vs did not receive a TJR recommendation, are shown in
Table II. Patients meeting the gold standard had higher symptom
levels. For knee/hip patients pooled, mean pain was 55.5 [95%
conﬁdence interval 54.2, 56.8] for those with TJR recommendation
vs 44.9 [43.2, 46.6] for those without TJR recommendation
(P< 0.0001). Mean functional impairment was 59.8 [58.7, 60.9] for
those with TJR recommendation vs 50.9 [49.3, 52.4], for those
without TJR recommendation (P< 0.0001). However, there was
a wide overlap in symptom levels between groups: almost 50% of
patients in the lowest decile of symptom scores were considered
candidates for TJR, whereas only 75% of patients in the highest
decile were considered candidates (Fig. 2 for online version only).
Symptom duration
The duration of symptoms at their current level was longer for
patients who did vs those who did not receive a TJR recommen-
dation (Table II).Table II
Symptom levels and radiographic severity according to recommendation for TJR
Knee OA: TJRþN¼ 628
Pain, ICOAP score 53.7 (52.0, 55.5)
Functional disability, HOOS-PS/KOOS-PS scores 58.1 (56.6, 59.7)
Pain, WOMAC subscale 56.4 (54.8, 57.9)
Function, WOMAC subscale 59.0 (57.4, 60.5)
Duration of symptoms at the current level, months 11.0 (6.2,15.2)
Radiographic joint space narrowing, N (%)*
<25% 3 (1.2)
25e50% 24 (10.0)
50e75% 85 (35.4)
>75% 128 (53.3)
Results are presented as mean (95% conﬁdence interval) except for radiographic result
100¼worst state. TJRþ: indication for TJR. TJR: no indication for TJR. For other abbrev
* % of available data.Univariate ROC curves
Taking pain and function separately, in the pooled hip/knee
population, it was not possible to determine relevant cut points
deﬁning recommendation for TJR (Fig. 1). The AUCs for the ROC
curves for pain and function vs the gold standard were 0.64 [95%
conﬁdence interval, 0.61, 0.67] and 0.63 [0.60, 0.66], respectively.
Thus, we had to accept the null hypothesis (i.e., that pain and
functional disability levels do not distinguish patients with vs
without a recommendation for TJR). The cut points had low diag-
nostic properties: e.g., for a speciﬁcity of 0.90, the sensitivity was
only 0.23 for pain and 0.24 for function; i.e., the positive and
negative likelihood ratios were only (1.17; 0.43) for pain and (1.18;
0.42) for physical disability.
After stratifying on radiographic severity, the AUCswere notmuch
improved (AUCs ranging from 0.65 to 0.68 for pain, and 0.60 to 0.63
for function, respectively) and cut points assessed had low diag-
nostic properties (data not shown).Correlation and relative importance of pain, functional disability
and radiographic status
Pain and functional disability were only moderately correlated
(R¼ 0.59, P< 0.0001), in the pooled hip/knee population, indi-
cating that these domains were not redundant.
In logistic regression, the coefﬁcients of regression of pain and
function were very similar (and signiﬁcant), indicating pain and
function are independent predictors of recommendation for TJR,with
similar weights. The coefﬁcients of regression were 0.015 for pain,
and 0.013 for function, respectively (both P< 0.0001). This result
justiﬁed our combining pain and functional status additively with
equal weights. Furthermore, radiographic severity was a signiﬁcant
independent predictor of recommendation for TJR (P< 0.0001) in the
pooled hip/knee population.ROC curves for the sum (painþ function)
With the sum (painþ function), it was also not possible to
determine cut points leading to relevant sensitivity/speciﬁcity in
the pooled hip/knee population: the AUC of the ROC curvewas 0.64
[95% conﬁdence interval, 0.61, 0.67], and for a speciﬁcity of 0.90 the
sensitivity was 0.27 (i.e., positive and negative likelihood ratios
were 2.70; 0.81).
When these analyses were stratiﬁed on radiographic severity, the
AUCs were not improved (AUCs ranging from 0.62 to 0.65 in the
different radiographic groups).Knee OA: TJRN¼ 502 Hip OA: TJRþN¼ 574 Hip OA: TJRN¼ 205
45.9 (44.0, 47.9) 57.3 (55.6, 59.1) 42.4 (39.1, 45.7)
52.3 (50.5, 54.0) 61.4 (59.8, 63.1) 47.4 (44.1, 50.7)
47.3 (45.3, 49.4) 59.8 (58.3, 61.4) 45.9 (42.4, 49.3)
50.3 (48.3, 52.4) 63.3 (61.7, 64.9) 48.7 (45.3, 52.2)
5.9 (2.3, 10.2) 6.9 (3.5, 11.5) 5.9 (2.1, 10.6)
64 (23.6) 3 (1.1) 25 (22.3)
70 (25.8) 14 (5.3) 22 (19.6)
74 (27.3) 75 (28.5) 39 (34.8)
63 (32.3) 171 (65.0) 26 (23.2)
s. Pain and functional disability were linearly transformed to 0e100 scores where
iations please see Table I.
Fig. 1. Ability of pain and functional impairment severity to predict indication for TJR in 1909 hip or knee OA patients. (a) pain, AUC for curve: 0.64 (95% conﬁdence interval,
0.61e0.67), (b) functional disability, AUC for curve: 0.63 (95% conﬁdence interval, 0.60e0.66).
L. Gossec et al. / Osteoarthritis and Cartilage 19 (2011) 147e154 151Sensitivity analyses
Several sensitivity analyses including use of alternate measures,
speciﬁcally theWOMACpain and function subscales (Supplementary
ﬁle 2); and changing the gold standard to true indication for TJR (i.e.,
not considering patients with severe status but comorbidities or
patient refusal as recommendations for TJR), did not modify the
results (data not shown).
The 75th percentile technique gave 89 as the value of the sum
(painþ function) deﬁning 75% of the population which had an
indication for TJR (respectively, 87 and 92, for knee and hip). When
applying the cut point of 89 to the whole population, 59% of the
patients were above that level; speciﬁcity was 0.51, sensitivity was
0.66, the positive and negative likelihood ratios were (1.34; 0.86).
Excluding patients from the United Kingdom did not modify the
conclusions (data not shown).
However, analysing the participants with hip or knee OA sepa-
rately, the association between symptoms and surgery was
stronger in the hip than in the knee (Fig. 2).
The AUCs of the ROC curves of the sum painþ function
were higher in hip OA [AUC, 0.70, 95% conﬁdence interval (CI),
0.66e0.75] than in knee OA (AUC, 0.60, 95% CI, 0.56e0.64).
However, even so, for hip patients the cut points assessed had
low diagnostic properties; e.g., the cut point leading to
a speciﬁcity of 90% was 66 (sum painþ function); for that cuta b
Fig. 2. Ability of the sum (painþ function) to predict indication for TJR, in knee and hip OA
(b) Hip, AUC for the ROC curve: 0.70 (95% CI, 0.66e0.75).point, for a speciﬁcity of 0.92, the sensitivity was only 0.31;
i.e., the positive and negative likelihood ratios were only (1.35;
0.23).
We also showed when analysing the centers separately
(regrouped by country), that in certain centers pain and function
were more strongly related to receipt of a TJR recommendation
than in other centers (e.g., AUC of the ROC curves for the sum
painþ function in hip OA, 0.75e0.86 in centers in Canada, France,
Germany and Australia as compared with 0.54e0.67 in centers in
The United Kingdom, the United States, the Netherlands and the
Czech Republic, Supplementary ﬁle 3).
Discussion
This large-scale international study was launched to determine
whether self-reported measures of pain and function could be used
to accurately identify patients with OA whose surgeons recom-
mended them for total hip or knee arthroplasty. The ﬁrst conclusion
of this work is that, indeed, among patients with hip and knee OA
referred to an orthopaedic surgeon, the level of symptoms was
higher among patients for whom TJR was indicated by the ortho-
paedic surgeon. Both the level of pain and self-reported functional
impairment were independently, though weakly, predictive of the
surgeon’s recommendation for TJR. The second conclusion is that
we could not ﬁnd a cut point for pain and or physical disability thatseparately (a) Knee, AUC for the ROC curve: 0.60 (95% conﬁdence interval, 0.56e0.64)
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did vs did not receive a TJR recommendation, as the AUCs for ROC
curves were low (<0.65). Radiographic severity, when available,
was a strong predictor of recommendation for TJR but stratifying by
radiographic joint status did not modify our conclusions.
Factors consistently predicting TJR are symptom levels and
radiographic severity. Less consistent predictors have included
gender, age and current treatment2,4e9. In the present study, the
mean values of pain and function in the group of patients consid-
ered candidates for surgery by the surgeons were consistent with
previously reported data in this area27e32. We conﬁrmed here that
both pain and functional disability are independent predictors of
recommendation by a surgeon for TJR; however, previous studies
did not include a control group to attempt to determine cut points
for patient-reported outcomes. In this study, using the ICOAP and
HOOS-PS/KOOS-PS, though pain and function were correlated
(as could be expected), the correlation was only moderate, which
indicates that pain and function using these scores are not redun-
dant when analysing OA patients. Furthermore, we also found that
the duration of the symptoms at their current level was an
important factor explaining indication for TJR. Other predictors
included radiographic severity, stiffness (assessed by WOMAC) and
OA disease duration (data not shown).
Despite the fact there was a difference in the level of symptoms
between the two groups (candidate for surgery yes/no) the overlap
between the two groups prevented us from proposing a speciﬁc cut-
off. Indeed, among these OA patients referred to an orthopaedic
surgeon, most patients were symptomatic. However, the surgeons
often decided that surgery was warranted even among the less
symptomatic patients (around 50% of the patients in the lower decile
of symptoms were recommended for TJR, Fig. 2 online), or that
surgery was not warranted even if the symptoms were severe (only
around 75% of these patients were considered surgery candidates).
This indicates that the level of symptoms in this population was not
the only driver for such a TJR indication30e32. Possibly, the surgeons
paid greater attention to the radiographic severity than to the
symptom levels10,27,33 and several studies have indicated a discor-
dance between radiographs and symptoms in lower-limb OA27,34e37.
In the present study however, stratifying the analyses on radio-
graphic severity did not modify our conclusions. Finally, the present
results indicated a stronger relationship between symptoms and
surgical indication in hip OA than in knee OA.
It is possible that the questionnaires used, the ICOAP and KOOS-PS/
HOOS-PS17e21 (whichwere not seen by the orthopaedic surgeon)may
assess different aspects of symptoms, than what the orthopaedic
surgeon usually assesses in the clinic; however, it is reassuring to note
that thesenewtools gave results very similar to theWOMACsubscales.
Indeed, the sensitivity analyses performed using WOMAC data
conﬁrmedourmain results. Perhaps also, other data related topatient-
reported outcomes could be relevant in the indication for TJR, such as
worsening of symptoms (e.g., minimal clinically important deteriora-
tion); however, we did not collect change in status in this study, but
only status at one time point, and persistence of that status, since we
felt that a decision for TJRwould bemore strongly basedon status than
on change. Clearly, in addition to symptomatic severity, many other
factors are as strong or stronger determinants of surgery9,38e41.
Furthermore, perhaps other aspects of symptomatic severity are taken
into account in the surgeons’ decision, e.g., the duration of symptoms
(whereas questionnaires have a short time-frame), or the ongoing
symptomatic treatment of the patient that may inﬂuence his/her
current level of symptoms4. Finally, the surgeonsmay have based their
surgical decision on joint mobility or peri-articular amyotrophy38,
which were not assessed here. There were clear differences across
centers and countries; these might be explained by several elements,
including differences in the health care systems, or characteristics/training of the surgeons. In all, the current study conﬁrms the wide
variability in the indication for TJR suggestedbystudiesofwhoactually
receives a TJR; these results provide evidence that variability in
surgeons’ recommendations and practices is an important contributor
to the clinical variability among TJR recipients.
This study has strengths and weaknesses. It is a large, interna-
tional study which enhances the external validity of our results. On
the other hand and as could be expected, there were differences
across centers and countries in terms of symptomatic severity and in
terms of the frequency of indication for TJR as assessed by the
orthopaedic surgeon9,32. We do not believe this is an important
limitation to the present results. Indeed, the objective here was to
develop international criteria reﬂecting a level of OA symptoms and
disability at which point TJR should be considered, for use as
outcomemeasure in clinical trials. In this context, it was necessary to
include patients from different backgrounds. In this study, one
possible bias is that only symptomatic OA patients were included
since the patients had to have deﬁnite OA to be included, andwere in
fact seeing an orthopaedic surgeon, generally to discuss a surgical
indication for their target joint (we do not have information
regarding if the patients were coming for the ﬁrst time, or for return
visits). Therefore the present study did not include many asymp-
tomatic patients which may explain the low predictive power of
symptomatic severity here. Indeed, symptom thresholds associated
with TJR in a more heterogeneous sample (including asymptomatic
patients) might be relevant for deﬁning endpoints for observational
studies. Nevertheless, the patients in the study presented with
a wide range of symptomatic severity, and only about half of them
were considered candidates for TJR. Several statistical techniques
and sensitivity analyses were performed, to further conﬁrm the
internal validity of our results; and the studywas not underpowered.
In this study, thegold standardwas the surgeon’s opinion regarding
need for TJR13,28.We considered that if surgerywas recommendedor if
the surgeon considered symptoms were severe enough for surgery
(although because of comorbidity10 or patient refusal9, the patientwas
not referred for surgery), a state of indication for TJR was attained.
However, we did not collect data regarding actual carrying-out of
surgery in these patients, which may differ widely2e10.
In conclusion, this large study indicates that among patients
referred to an orthopaedic surgeon to discuss TJR, the level of
symptoms was higher among patients for whom TJR was indicated
by the surgeon, but there was no cut point for pain and functional
disability allowing to discriminate between patients with or
without an indication for TJR.
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